Goldman JM - Search Results

1

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.

Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Müller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA; IRIS Investigators. Hochhaus A, et al. Among authors: goldman jm. Leukemia. 2009 Jun;23(6):1054-61. doi: 10.1038/leu.2009.38. Epub 2009 Mar 12. Leukemia. 2009. PMID: 19282833 Clinical Trial.

2

Monitoring the efficiency of interferon-alpha therapy in chronic myelogenous leukemia (CML) patients by competitive polymerase chain reaction.

Hochhaus A, Lin F, Reiter A, Skladny H, Hehlmann R, Goldman JM, Cross NC. Hochhaus A, et al. Among authors: goldman jm. Leukemia. 1997 Apr;11 Suppl 3:541-4. Leukemia. 1997. PMID: 9209451

3

KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.

Marin D, Gabriel IH, Ahmad S, Foroni L, de Lavallade H, Clark R, O'Brien S, Sergeant R, Hedgley C, Milojkovic D, Khorashad JS, Bua M, Alsuliman A, Khoder A, Stringaris K, Cooper N, Davis J, Goldman JM, Apperley JF, Rezvani K. Marin D, et al. Among authors: goldman jm. Leukemia. 2012 Feb;26(2):296-302. doi: 10.1038/leu.2011.180. Epub 2011 Aug 16. Leukemia. 2012. PMID: 21844874

4

p53 in chronic myeloid leukemia cell lines.

Bi S, Hughes T, Bungey J, Chase A, de Fabritiis P, Goldman JM. Bi S, et al. Among authors: goldman jm. Leukemia. 1992 Aug;6(8):839-42. Leukemia. 1992. PMID: 1640738

5

Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines.

O'Brien SG, Kirkland MA, Melo JV, Rao MH, Davidson RJ, McDonald C, Goldman JM. O'Brien SG, et al. Among authors: goldman jm. Leukemia. 1994 Dec;8(12):2156-62. Leukemia. 1994. PMID: 7808004

6

Autografting in chronic myeloid leukaemia.

O'Brien SG, Goldman JM. O'Brien SG, et al. Among authors: goldman jm. Blood Rev. 1994 Jun;8(2):63-9. doi: 10.1016/s0268-960x(05)80009-8. Blood Rev. 1994. PMID: 7950476 Review.

7

Residual Ph-negative stem cells in chronic myeloid leukemia--sometimes or always?

Goldman JM, O'Brien SG. Goldman JM, et al. Stem Cells. 1993 Oct;11 Suppl 3:4-7. doi: 10.1002/stem.5530110903. Stem Cells. 1993. PMID: 8298477 Review.

8

Expression of the LH2 gene in chronic myeloid leukaemia cells.

Al-Jehani F, Hochhaus A, Spencer A, Goldman JM, Melo JV. Al-Jehani F, et al. Among authors: goldman jm. Leukemia. 1996 Jul;10(7):1122-6. Leukemia. 1996. PMID: 8683990

9

Expression of interferon regulatory factor (IRF) genes and response to interferon-alpha in chronic myeloid leukaemia.

Hochhaus A, Yan XH, Willer A, Hehlmann R, Gordon MY, Goldman JM, Melo JV. Hochhaus A, et al. Among authors: goldman jm. Leukemia. 1997 Jul;11(7):933-9. doi: 10.1038/sj.leu.2400723. Leukemia. 1997. PMID: 9204971

10

Rarity of dominant-negative mutations of the G-CSF receptor in patients with blast crisis of chronic myeloid leukemia or de novo acute leukemia.

Carapeti M, Soede-Bobok A, Hochhaus A, Sill H, Touw IP, Goldman JM, Cross NC. Carapeti M, et al. Among authors: goldman jm. Leukemia. 1997 Jul;11(7):1005-8. doi: 10.1038/sj.leu.2400697. Leukemia. 1997. PMID: 9204982

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

904 results

Search Page